Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Johan Sandell"'
Autor:
Anton Lindberg, Emily Murrell, Junchao Tong, N. Scott Mason, Daniel Sohn, Johan Sandell, Peter Ström, Jeffrey S. Stehouwer, Brian J. Lopresti, Jenny Viklund, Samuel Svensson, Chester A. Mathis, Neil Vasdev
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Positron emission tomography (PET) imaging of tau aggregation in Alzheimer’s disease (AD) is helping to map and quantify the in vivo progression of AD pathology. To date, no high-affinity tau-PET radiopharmaceutical has been optimized for
Externí odkaz:
https://doaj.org/article/565281a593e843aeae917584e9015b15
Autor:
Brian J. Lopresti, N. Scott Mason, Laszlo Rakos, Anton Lindberg, Johan Sandell, William E. Klunk, Chester A. Mathis, Neil Vasdev, Daniel Sohn, Jeffrey S. Stehouwer, Ashley C Knight, April Radelet, Alexander Sandberg, Per Hammarström, Junchao Tong, Samuel P.S. Svensson
Publikováno v:
ACS Chemical Neuroscience. 12:596-602
CBD-2115 was selected from a library of 148 compounds based on a pyridinyl-indole scaffold as a first-in-class 4R-tau radiotracer. In vitro binding assays showed [3H]CBD-2115 had a KD value of 6.9 nM and a nominal Bmax of 500 nM in 4R-tau expressing
Autor:
Anton, Lindberg, Ashley C, Knight, Daniel, Sohn, Laszlo, Rakos, Junchao, Tong, April, Radelet, N Scott, Mason, Jeffrey S, Stehouwer, Brian J, Lopresti, William E, Klunk, Johan, Sandell, Alexander, Sandberg, Per, Hammarström, Samuel, Svensson, Chester A, Mathis, Neil, Vasdev
Publikováno v:
ACS Chem Neurosci
CBD-2115 was selected from a library of 148 compounds based on a pyridinyl-indole scaffold as a first-in-class 4R-tau radiotracer. In vitro binding assays showed [(3)H]CBD-2115 had a K(D) value of 6.9 nM and a nominal B(max) of 500 nM in 4R-tau expre
Autor:
Jeff Stehouwer, Junchao Tong, Daniel Sohn, Ashley C Knight, Neil Vasdev, Chester A. Mathis, William E. Klunk, Laszlo Rakos, Samuel P.S. Svensson, Johan Sandell, Anton Lindberg, Brian J. Lopresti, Per Hammarström, N. Scott Mason, April Radelet, Alexander Sandberg
Publikováno v:
Nuclear Medicine and Biology. :S9-S10
Publikováno v:
Molecular Imaging and Biology. 19:837-845
Purpose LRRK2 (leucine-rich repeat kinase 2) has recently been proven to be a promising drug target for Parkinson’s disease (PD) due to an apparent enhanced activity caused by mutations associated with familial PD. To date, there have been no repor
Publikováno v:
Molecular imaging and biology. 19(6)
Publikováno v:
Molecular imaging and biology. 19(6)
LRRK2 (leucine-rich repeat kinase 2) has recently been proven to be a promising drug target for Parkinson's disease (PD) due to an apparent enhanced activity caused by mutations associated with familial PD. To date, there have been no reports in whic
Autor:
Johan Sandell
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 56:321-324
In support of a metabolite study, the β-amyloid plaque neuroimaging positron-emission tomography radioligand AZD4694 was labeled with carbon-14 in 10 radiosynthetic steps starting from radiolabeled carbon dioxide. [(14)C]AZD4694 was labeled in the b
Autor:
Peter Johnström, Britt-Marie Swahn, David Pyring, Magnus Schou, Margareta Bergh, Jan A.M. Neelissen, Anders Juréus, Samuel P.S. Svensson, Johan Sandell, Fredrik Jeppsson
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:4332-4337
The synthesis and SAR of new β-amyloid binding agents are reported. Evaluation of important properties for achieving good signal-to-background ratio is described. Compounds 27, 33, and 36 displayed desirable lipophilic and pharmacokinetic properties
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 55:80-83
The γ-secretase inhibitor dibenzazepine (DBZ) and the γ-secretase modulators 1 and AZ8349 were prepared as tritium-labeled compounds with high specific activity and radiochemical purity. [3H]DBZ was labeled via an iodinated precursor, [3H]1 was lab